S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
S&P 500   4,076.57
DOW   34,395.01
QQQ   293.72
Is Apple Going To Rally Into Year End?
The single greatest medical breakthrough of all time? (Ad)
25 Ways to Improve Your Financial Situation in 1 Hour
La-Z-Boy Reclines To More Comfortable Levels 
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
Are the Short Sellers Still Right About Mullen Automotive stock? 
Is The Recovery Rally Here For SoFi?
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Biden administration presses senators to avert rail strike
Trump Org. defense lawyer scolded for using struck testimony
NASDAQ:NBIX

Neurocrine Biosciences - NBIX Stock Forecast, Price & News

$126.31
-0.75 (-0.59%)
(As of 12/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$125.65
$129.29
50-Day Range
$100.57
$127.06
52-Week Range
$71.88
$129.29
Volume
654,328 shs
Average Volume
795,103 shs
Market Capitalization
$12.14 billion
P/E Ratio
221.60
Dividend Yield
N/A
Price Target
$124.00

Neurocrine Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.59 Rating Score
Upside/​Downside
1.8% Downside
$124.00 Price Target
Short Interest
Healthy
3.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.32mentions of Neurocrine Biosciences in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$14.70 M Sold Last Quarter
Proj. Earnings Growth
97.41%
From $1.93 to $3.81 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

430th out of 1,047 stocks

Biological Products, Except Diagnostic Industry

68th out of 173 stocks

NBIX stock logo

About Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL - Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.

Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Stock News Headlines

Is Mid-Cap Neurocrine Biosciences A Buy After Blowout Q3 Report?
Neurocrine Biosciences trended higher with the broad market Thursday, coming within a penny of Tuesday’s high of $125.99. It is forming a bullish channel.
Bear Market Expert Reveals His #1 Stock for November 2023 
"I went from the brink of bankruptcy to wealthy – thanks to one type of stock". Get his top pick here. pixel
Could Pfizer Stock Help You Retire a Millionaire?
3 Reasons Growth Investors Will Love Neurocrine (NBIX)
Bear Market Expert Reveals His #1 Stock for November 2023 
"I went from the brink of bankruptcy to wealthy – thanks to one type of stock". Get his top pick here. pixel
We're Adjusting Our Strategy for Neurocrine Biosciences
Neurocrine Biosciences (NBIX) Q3 Earnings Lag Estimates
See More Headlines
Receive NBIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter.

NBIX Company Calendar

Last Earnings
11/01/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/10/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NBIX
CUSIP
64125C10
Employees
900
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$124.00
High Stock Price Forecast
$154.00
Low Stock Price Forecast
$94.00
Forecasted Upside/Downside
-1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.59
Research Coverage
17 Analysts

Profitability

Net Income
$89.60 million
Pretax Margin
5.92%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$1.29 per share
Book Value
$16.07 per share

Miscellaneous

Free Float
91,904,000
Market Cap
$12.14 billion
Optionable
Optionable
Beta
0.52

Key Executives

  • Dr. Kevin C. Gorman Ph.D. (Age 64)
    CEO & Director
    Comp: $1.58M
  • Mr. Matthew C. AbernethyMr. Matthew C. Abernethy (Age 42)
    Chief Financial Officer
    Comp: $906.76k
  • Dr. Jude Onyia Ph.D. (Age 58)
    Chief Scientific Officer
    Comp: $621.66k
  • Mr. Eric S. BenevichMr. Eric S. Benevich (Age 57)
    Chief Commercial Officer
    Comp: $805k
  • Dr. Eiry Wyn Roberts M.D. (Age 58)
    Chief Medical Officer
    Comp: $925.46k
  • Dr. Dimitri E. GrigoriadisDr. Dimitri E. Grigoriadis (Age 64)
    Chief Research Officer
  • Jane Sorensen
    Head of Investor Relations
  • Mr. Darin M. LippoldtMr. Darin M. Lippoldt (Age 56)
    Chief Legal Officer & Corp. Sec.
  • Mr. Kyle W. GanoMr. Kyle W. Gano (Age 49)
    Chief Bus. Devel. and Strategy Officer
  • Ms. Julie S. CookeMs. Julie S. Cooke (Age 56)
    Chief HR Officer













NBIX Stock - Frequently Asked Questions

Should I buy or sell Neurocrine Biosciences stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 7 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NBIX shares.
View NBIX analyst ratings
or view top-rated stocks.

What is Neurocrine Biosciences' stock price forecast for 2023?

17 equities research analysts have issued 1-year price targets for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $94.00 to $154.00. On average, they predict the company's share price to reach $124.00 in the next year. This suggests that the stock has a possible downside of 1.8%.
View analysts price targets for NBIX
or view top-rated stocks among Wall Street analysts.

How have NBIX shares performed in 2022?

Neurocrine Biosciences' stock was trading at $85.17 on January 1st, 2022. Since then, NBIX shares have increased by 48.3% and is now trading at $126.31.
View the best growth stocks for 2022 here
.

When is Neurocrine Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, February 10th 2023.
View our NBIX earnings forecast
.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) released its earnings results on Monday, November, 1st. The company reported $0.23 earnings per share for the quarter, missing analysts' consensus estimates of $0.51 by $0.28. The firm earned $296 million during the quarter, compared to analyst estimates of $297.02 million. Neurocrine Biosciences had a trailing twelve-month return on equity of 4.06% and a net margin of 4.19%. The company's quarterly revenue was up 14.5% on a year-over-year basis. During the same quarter last year, the business posted ($0.62) EPS.

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (12.53%), Vanguard Group Inc. (9.36%), State Street Corp (3.92%), Bellevue Group AG (2.97%), Bank of New York Mellon Corp (1.81%) and Price T Rowe Associates Inc. MD (1.52%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter.
View institutional ownership trends
.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $126.31.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $12.14 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.57 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

The company employs 900 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602.

This page (NASDAQ:NBIX) was last updated on 12/2/2022 by MarketBeat.com Staff